Edwards Lifesciences is a global leader in innovative medical technology, specializing in heart valve repair and replacement, as well as critical care monitoring
The company focuses on developing advanced products to enhance the quality of heart surgery and improve patient outcomes. Edwards Lifesciences is dedicated to addressing cardiovascular disease, which remains a leading cause of death worldwide, by providing solutions that enable less invasive procedures and better management of patients with heart-related conditions. Through continuous research and development, the company strives to transform patient care in the fields of heart disease and surgical intervention.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company projects continued expansion in 2025.
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New York.
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Jan. 13-17, 2025.
Edwards Lifesciences outlines 2025 growth strategy, emphasizing innovations in TAVR and TMTT therapies, with a projected sales growth of 8%-10% and expanded patient care.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Boston Scientific's ACURATE IDE trial results showed a 16.16% composite rate for mortality, stroke, or rehospitalization, not meeting non-inferiority versus controls.
Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks.
